icon-folder.gif   Conference Reports for NATAP  
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
C-EDGE TN: Impact of 12-Week Oral Regimen of Elbasvir (EBR, MK-8742) / Grazoprevir (GZR, MK-5172) on Patient-Reported Outcomes (PROs) in Treatment-Naïve Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 4, or 6 Infection
  Reported by Jules Levin
AASLD Nov 13-17 San Francisco
Jean Marie Arduino; Yang Wang; Deborah D. Brown; Shazia Khawaja; Elisa Martinez; Joan R. Butterton; Michael Robertson; Chizoba Nwankwo; T. Christopher Mast 1Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA
from Jules: its interesting comparing the PROs for mono-infected vs co-infected patients in these Merck studies: for example, social functioning declined in HIV+ treated patients in coinfection PRO study while improved in this mono infection PRO study; role limitations; emotional declined in HIV+ but appears stable, no change in mono infected. Mental health remained stable through treatment and appeared to improve at week 12 followup in mono infected but in HIV+ the overall affect was a decline in mental health, mental health declined throughout treatment and week 12 followup and then appeared to improve at followup week 24. in HIV+. Fatigue appeared to appreciably improve steadily for mono infected through treatment & followup but overall there appeared to be little if any improvement for HIV+, but during treatment fatigue worsened and then improved during followup. Also, look at differences in Bodily pain. Of note look at EQ-VAS (Overall Health) where there was a steady improvement through treatment & followup in moninfected while in HIV+ it improved on treatment then declined in followup from that improvement but with an overall slight improvement. Work impairment improved steadily in mono infected but was up in HIV+ during treatment and in followup improved and then worsened.